Navigation Links
PARI Pharma Completes Successful Clinical Trials for Tobramycin 100 & Investigational eFlow for CF
Date:11/10/2008

d to see similar lung deposition and safety profiles while using a lower dose and volume of tobramycin," said Dr. Allan Coates, lead researcher from the Hospital for Sick Kids in Toronto, Canada. "Technology is really working on the side of the patient with this formulation and the resulting reductions in treatment times. Lack of patient adherence to recommended therapy is a major challenge in cystic fibrosis, especially in adolescents, with the length of treatment time given as the major excuse. With equivalent delivery but in a much shorter time, there are improved chances for greater adherence to prescribed therapy."

Based on the successful results of the Phase I and Phase II clinical trials, regulatory bodies in Europe welcomed the advantages and benefit of PARI Tobramycin 100 for CF patients and recommended moving forward with a Phase III study to demonstrate therapeutic efficacy and equivalence to TOBI.

PARI Pharma is currently in discussions with multinational pharmaceutical companies to evaluate the efficacy of PARI Tobramycin 100 in a Phase III clinical study and to ultimately make this next-generation treatment available to CF patients worldwide.

The Phase I clinical trial was a randomized, open label, crossover, single-dose deposition study of PARI Tobramycin 100 in an Investigational eFlow versus TOBI/LC PLUS in 16 cystic fibrosis patients, including 8 adults and 8 children. The study was conducted by Dr. Allan Coates at the Hospital for Sick Kids in Toronto, Canada. Tobramycin lung deposition for both applications was between 46mg and 47mg. There was also no difference in the ratio of peripheral to central lung deposition between both drug products and delivery systems. Results from the study were presented at the North American Cystic Fibrosis Conference in October.

The Phase II clinical trial, a randomized, open label, parallel group, non-inferiority, 28-day pharmacokinetic study evaluated the serum levels after twice daily
'/>"/>

SOURCE PARI Pharma
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3 4

Related medicine news :

1. Anemia and tropical diseases; Is pharmacogenomics ready for the clinic?
2. Mylan Commences Tender Offers and Consent Solicitations for Its 5.750% Senior Notes Due 2010 and 6.375% Senior Notes Due 2015 in Connection With Its Proposed Acquisition of Mercks Generic Pharmaceutical Business
3. Arena Pharmaceuticals to Present at the NewsMakers in the Biotech Industry Conference
4. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Zyloprim(R)
5. The Pharma & Life Sciences Best Practice Database: an Industry Resource for Successful Techniques and Performance Benchmarks for Reaching the Top
6. Schering-Plough/Merck Pharmaceuticals Announce FDA Filing Acceptance of New Drug Application for Loratadine/Montelukast Tablet
7. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Adipex-P(R)
8. National Pharmaceutical Council Announces New Strategic Focus, Search for New Leadership
9. AKELA Pharma Inc. announces positive results for the extension part of its Phase IIb Fentanyl TAIFUN(R) trial
10. Caraco Pharmaceutical Laboratories, Ltd. Announces FDA Approval to Market Generic Version of Coreg(R)
11. Innocoll Agrees the Sale of its CollaRx(R) GENTAMICIN SURGICAL IMPLANT and European Sales and Marketing Infrastructure to EUSA Pharma
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/25/2013)... It's not astonishing that holidays are amongst the ... endless, from family, friends and co-workers. Between the parties ... than their parents can afford, parties to arrange, and ... birthdays, anniversaries and it seems like an eternal cycle ... tired and income can’t catch up to the expenses ...
(Date:5/25/2013)... Idaho (PRWEB) May 25, 2013 A ... prevalent type of peripheral neuropathy. According to neuropathy expert ... , it is estimated that the disorder affects almost ... common complication arising from Diabetes. The high blood sugar ... Diabetes and patients suffering from it usually tend to ...
(Date:5/25/2013)... Forney, United States (PRWEB) May 25, 2013 ... oldest and largest underground shelter company in the ... and composite underground structures for over 35 years. ... of PROTECTION, U.S. Handbook of NBC Weapon Fundamentals ... is the United States’ bible on shelter engineering. ...
(Date:5/25/2013)... Pradaxa lawsuits filed on behalf ... bleeding while using the blood thinner continue to mount in ... of Illinois, Bernstein Liebhard LLP reports. According to a ... had been filed in the litigation as of ... by the Court on May 15th. ( In Re: Pradaxa ...
(Date:5/25/2013)... May 25, 2013 Many orthodontists have ... wonder where exactly that cloud is. Most people ... up with to provide their cloud service and support ... provide the service they're selling, they'd be wrong. ... (a secure, redundant facility that houses servers and ...
Breaking Medicine News(10 mins):Health News:TheBeautyPlace.com Debuts Their Brand New Beauty Kits 2Health News:Diabetic Neuropathy treatment hits new grounds- Neuracel launches the complete natural treatment 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 2Health News:Radius Engineering International Inc. Offers Tools to Stay Safe and Recover From Any Disaster 3Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 2Health News:Pradaxa Lawsuits Mount, as Filings in Federal Pradaxa Side Effect Litigation Exceed 800, Bernstein Liebhard LLP Reports 3Health News:Cirrus Ortho Launches Cloud Computing for Orthodontic Industry That is Unlike Any Other 2
... PRINCETON, N.J., Feb. 19 Medarex, Inc. (Nasdaq: ... its 2008 fourth quarter and year-end results on ... the financial markets close. Following the release, Medarex,s ... webcast at 4:30 p.m. Eastern Time. To access ...
... CVD ) today announced that it has elected ... Dr. Sheares is former chief executive officer and member of ... company that marketed a portfolio of branded cardiovascular medicines. Prior ... Health division of Merck and Co., Inc., where he led ...
... to know the least, survey finds, , , THURSDAY, Feb. 19 (HealthDay ... of a stroke and what to do if they suspect one ... research. , Older people and those who,ve already had a stroke ... the symptoms of a stroke and know to immediately call 911. ...
... PLC, a subsidiary of MGT Capital Investments, Inc. ... development of Computer-Aided Detection (CAD) and image analysis ... of disease, today announces the following restructuring of ... Rowley, currently Chief Financial Officer, becomes Chief Executive ...
... Feb. 19 A groundbreaking new survey sponsored by ... 82% of young adults aged 18-30 plan to get ... 40% of first marriages end in divorce. Why?"There is ... reality of getting or being married," says Mary Myrick, ...
... 2009 A new study released today found blacks ... replacement, an important intervention for reducing pain and improving ... study also found total knee replacements are increasing substantially ... the research underscores the need for healthcare providers and ...
Cached Medicine News:Health News:Medarex to Announce 2008 Fourth Quarter and Year-End Financial Results on Wednesday, February 25, 2009 2Health News:Covance Elects Bradley T. Sheares to Company's Board of Directors 2Health News:Know the Warning Signs of Stroke? Most Don't. 2Health News:Medicsight PLC Restructures Management Team 2Health News:Medicsight PLC Restructures Management Team 3Health News:Young People Want 'Happily Ever After,' but Lack Skills to Make Marriage Work 2Health News:New study finds blacks still lag in obtaining total knee replacements for arthritis 2Health News:New study finds blacks still lag in obtaining total knee replacements for arthritis 3
(Date:5/23/2013)... , May 23, 2013  Haemonetics Corporation (NYSE: ... , CFO & EVP-Business Development, will present at The Deutsche ... Boston, MA on May 29, 2013 ... ) The public may access Mr. Lindop,s ... About Haemonetics Haemonetics (NYSE: HAE ...
(Date:5/23/2013)... May 23, 2013  TeamHealth Medical Call Center ... and nurse advice lines, announces its newly formed ... nursing and administrative leaders, provides clinical expertise to ... cost-effective services for hospital clients, physician clients and ... system evolves, it,s imperative to continuously advance our ...
(Date:5/23/2013)... 23, 2013  Every day, their baby stopped breathing, his ... lungs. April and Bryan Gionfriddo watched ... "Quite a few doctors said he had a ... April Gionfriddo , about her now 20-month-old son, ... work, we would take it and run with it." ...
Breaking Medicine Technology:TeamHealth Medical Call Center Forms Clinical Advisory Committee 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 2Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 3Baby's life saved with groundbreaking 3D printed device from U-M that restored his breathing 4
... Catalyst,Biosciences, Inc., a pioneer in the discovery and ... that it has,selected CB 813, an improved, second-generation ... candidate for the treatment of,acute bleeding in hemophilia ... protease platform technologies and know-how., CB 813 ...
... "fast track" ... drug, ... for second-round test-phase production of a,FDA-designated "fast track" drug candidate to treat ... through acts of bio-warfare,or bio-terrorism., (Logo: http://www.newscom.com/cgi-bin/prnh/20050801/ALBEMARLELOGO ), ...
Cached Medicine Technology:Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia 2Catalyst Biosciences Selects Drug Development Candidate in Factor VIIa Program for Hemophilia 3Albemarle Optimizes Smallpox Drug Candidate for SIGA 2Albemarle Optimizes Smallpox Drug Candidate for SIGA 3
... is a smart, sophisticated and compact medium throughput ... effective chemistry analyser in its class! It is ... 230 tests per hour. The DataPro runs all ... normal biochemistry laboratory and runs a wide range ...
... Our manufacturing process makes ... nanocrystals ensuring magnetic responsiveness. ... with the rigid core ... magnetic aggregation occurs upon ...
... The BcMag Streptavidin magnetic beads ... capture of biotinylated molecules such ... protein from cell lysates or ... its highly dispersed, it can ...
... m Dynabeads with covalently bound ... any biotinylated target. The Dynabeads® ... area, high capacity, magnetic pull ... during incubation. The MyOne™ products ...
Medicine Products: